Tudriqev (RP1): FDA Approval of Second Oncolytic Virus for Melanoma

On August 6, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg, formerly RP1), developed by Replimune Group Inc., in combination with nivolumab (Opdivo, Bristol Myers Squibb) for adult patients with unresectable locally advanced or metastatic cutaneous melanoma that progressed on or after an anti-PD-1-containing regimen. This landmark decision marks only the second FDA approval of an oncolytic virus in U.S. history—nearly eleven years after the October 2015 approval of Amgen's Imlygic (talimogene laherparepvec / T-VEC).

Approval was based on objective response rate (ORR) and duration of response (DOR) data from the single-arm registrational cohort of the Phase 1/2 IGNYTE trial (NCT03767348), published in the Journal of Clinical Oncology (Wong et al., 2025). Among 91 efficacy-evaluable patients with confirmed progression after at least 8 consecutive weeks of prior anti-PD-1 therapy, the combination produced a confirmed ORR of 24.2% (95% CI: 15.8%–34.3%) and a median duration of response of 14.1 months (95% CI: 10.7 months to not reached). Replimune set an anticipated wholesale acquisition list price of approximately $450,000 per course of therapy (based on median tumor-burden dosing) and announced plans to initiate commercial distribution within roughly 60 days.

For oncology practices, pharmacy and therapeutics (P&T) committees, and market access directors, Tudriqev introduces a highly differentiated, off-the-shelf intratumoral immunotherapy into a post-PD-1 setting previously dominated by systemic salvage chemotherapy, clinical trial enrollment, or Iovance Biotherapeutics' autologous tumor-infiltrating lymphocyte (TIL) cell therapy Amtagvi (lifileucel, priced at ~$562,000 to $563,000). However, the approval also presents immediate operational and reimbursement complexities: intratumoral buy-and-bill mechanics, temporary unclassified billing codes (prior to a permanent CMS HCPCS J-code), cold-chain viral containment protocols, and regulatory withdrawal risk tied to the ongoing confirmatory Phase 3 IGNYTE-3 trial.

                      Tudriqev (RP1) Overview & Access Profile
                                         │
        ┌────────────────────────────────┼────────────────────────────────┐
        │                                │                                │
  [Mechanism]                      [Clinical Data]                  [Commercial & Access]
  • Genetically engineered         • Phase 1/2 IGNYTE (NCT03767348) • List Price: ~$450,000/course
    HSV-1 oncolytic virus          • 91 evaluable post-PD-1 pts     • Outpatient intratumoral injection
  • Encodes GALV-GP-R(-)           • Confirmed ORR: 24.2%           • Combined with IV nivolumab
    fusogenic protein + GM-CSF     • Median DOR: 14.1 months        • Buy-and-bill medical benefit
  • Dual gene deletions            • CTGTAC AdCom Vote: 10-3        • Confirmatory: Phase 3 IGNYTE-3
    (ICP34.5 / ICP47)              • Accelerated Approval (08/06/26)• Temporary unclassified HCPCS

---

What is Tudriqev (RP1) and how does an oncolytic virus work as cancer therapy?

Oncolytic immunotherapy represents a distinct modality designed to turn immunologically "cold" or immune-checkpoint-refractory tumors "hot." Rather than acting solely as a direct cytotoxic agent or a systemic immune disinhibitor, an oncolytic virus combines selective intratumoral viral replication with potent local immune activation and systemic antigen presentation.

Tudriqev is derived from a proprietary clinical isolate of herpes simplex virus type 1 (HSV-1, strain RH018) that was chosen for its natural oncolytic potency and fast replication kinetics. The viral genome was genetically engineered with three targeted modifications:

1. Deletion of ICP34.5 (Infected Cell Protein 34.5): ICP34.5 is the primary neurovirulence factor in HSV-1 that blocks the host cell's protein kinase R (PKR) antiviral shutdown pathway. Deletion of ICP34.5 prevents the virus from replicating in healthy, non-malignant cells where intact PKR signaling halts viral protein synthesis. In contrast, cancer cells harbor disrupted PKR and interferon pathways, permitting unrestricted viral replication and selective oncolysis.
2. Deletion of ICP47 (Infected Cell Protein 47): In wild-type HSV-1, ICP47 binds to and inhibits the Transporter Associated with Antigen Processing (TAP), preventing MHC Class I presentation of viral and tumor antigens on the cell surface. By deleting ICP47, Tudriqev restores and enhances TAP-mediated peptide loading, driving intense MHC Class I upregulation and making infected tumor cells highly visible to CD8+ cytotoxic T lymphocytes. Deletion of ICP47 also places the adjacent HSV-1 US11 gene under early viral promoter control, further enhancing viral replication without restoring neurovirulence.
3. Insertion of Transgenes: GALV-GP-R(-) and GM-CSF: Tudriqev encodes two distinct therapeutic payloads:
   • GALV-GP-R(-): A truncated, hyper-fusogenic glycoprotein derived from the gibbon ape leukemia virus. When expressed on the surface of infected tumor cells, it triggers rapid cell-to-cell fusion, forming large multinucleated syncytia that kill adjacent non-infected tumor cells and release large waves of tumor-associated antigens (TAAs) and neoantigens.
   • GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor): Human GM-CSF secreted into the tumor microenvironment recruits, differentiates, and activates dendritic cells and other antigen-presenting cells (APCs), accelerating systemic anti-tumor immune priming.

                    Tudriqev Intratumoral & Abscopal Mechanism
                                         │
             ┌───────────────────────────┴───────────────────────────┐
             │                                                       │
   [Local Injected Tumor]                                  [Distant Uninjected Lesions]
   1. Intratumoral HSV-1 infection                        1. APCs migrate to lymph nodes
   2. Selective replication & oncolysis                   2. CD8+ T-cell priming against TAAs
   3. GALV-GP-R(-) syncytia formation                     3. Nivolumab blocks PD-1 inhibition
   4. GM-CSF secretion & TAA release                      4. Systemic tumor regression (Abscopal)

When injected directly into accessible cutaneous, subcutaneous, or nodal melanoma lesions, Tudriqev lyses local tumor cells and releases patient-specific neoantigens into an inflamed microenvironment. Co-administered systemic Opdivo (nivolumab) access and billing removes the inhibitory brake on newly primed neoantigen-specific T cells, allowing activated CD8+ T cells to traffic systemically and mediate tumor regression in distant, uninjected visceral lesions (the classic abscopal effect).

---

How does Tudriqev's engineered construct compare to Imlygic (T-VEC)?

To understand why Tudriqev succeeded in the post-anti-PD-1 setting where earlier viral platforms struggled, it is essential to compare its molecular construct directly with Imlygic (talimogene laherparepvec / T-VEC), which received FDA approval in 2015 for injectable melanoma lesions based on the Phase 3 OPTiM trial.

The crucial molecular divergence is the addition of the GALV-GP-R(-) fusogenic protein. In preclinical and translational models, cell fusion mediated by GALV-GP-R(-) increased the immunogenicity of tumor cell death by orders of magnitude compared to oncolysis alone. This enhanced antigen release explains why Tudriqev plus nivolumab generated systemic, durable responses in patients whose tumors had already developed resistance to prior anti-PD-1 checkpoint blockade.

---

What did the IGNYTE trial show, and why was approval accelerated?

The basis for Tudriqev's FDA accelerated approval rests on the anti-PD-1-failed melanoma cohort of the Phase 1/2 IGNYTE registrational study (NCT03767348).

Patient Population & Baseline Characteristics

The cohort enrolled 140 adult patients with histologically confirmed, unresectable Stage IIIB to Stage IV cutaneous melanoma. Crucially, all patients had documented disease progression while receiving prior anti-PD-1 therapy (either pembrolizumab or nivolumab, alone or in combination with ipilimumab or LAG-3 inhibitors). Key eligibility criteria required:

• At least 8 consecutive weeks of prior anti-PD-1 therapy.
• Documented progressive disease according to RECIST v1.1.
• At least one injectable cutaneous, subcutaneous, or nodal lesion ($\ge 10\text{ mm}$ or $\ge 5\text{ mm}$ for cutaneous).
• For the primary efficacy analysis, at least one uninjected measurable target lesion was required to evaluate systemic abscopal anti-tumor response.

A total of 91 patients met all strict criteria for the efficacy-evaluable population. Baseline disease burden was heavy: approximately 80% had Stage IV disease, 54% were PD-L1 negative, and visceral involvement was common, including lung metastases (45%) and liver lesions (24%).

Efficacy Endpoints & Response Rates

The primary endpoint was confirmed objective response rate (ORR) assessed by an Independent Central Review (ICR) using RECIST v1.1. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), disease control rate (DCR), and overall survival (OS).

                   IGNYTE Primary Efficacy Outcomes (n=91)
                                      │
                  ┌───────────────────┴───────────────────┐
                  │                                       │
            [Confirmed ORR]                          [Median DOR]
                 24.2%                              14.1 Months
        (95% CI: 15.8%–34.3%)               (95% CI: 10.7–Not Reached)

• Confirmed ORR: 24.2% (95% CI: 15.8% to 34.3%), assessed by Independent Central Review using RECIST v1.1.
• Median Duration of Response (mDOR): 14.1 months (95% CI: 10.7 months to not reached).
• Abscopal Activity: Systemic responses were observed in distant, uninjected visceral lesions, including liver and lung metastases—an important signal that the intratumoral virus primes systemic anti-tumor immunity rather than acting only at the injection site.

An updated 3-year survival analysis of the broader IGNYTE anti-PD-1-failed melanoma cohort ($n \approx 47$), presented to support the third resubmission, reported an ORR of 33.6% (16.4% complete responses; 17.1% partial responses), a median DOR of 24.8 months, and a median overall survival of 32.9 months—data that helped persuade the advisory committee despite FDA reviewers' concerns. The FDA-labeled efficacy-evaluable population ($n=91$) remains the basis of the 24.2% ORR on the approved label.

Safety & Tolerability Profile

The safety profile of Tudriqev plus nivolumab was consistent with the known mechanisms of intratumoral HSV-1 and systemic PD-1 blockade. Per the FDA-approved label, adverse events in IGNYTE were predominantly grade 1–2 and transient; the most common were fatigue, pyrexia, chills, nausea, and injection-site reactions, with no common grade 4 or 5 events. Serious adverse reactions occurred in 35% of treated patients. The label carries specific warnings for herpetic infection, accidental exposure of close contacts to the live virus, and injection-related visceral injury—reflecting that Tudriqev is a replication-competent, genetically modified HSV-1 administered by direct intratumoral injection. Immune-mediated adverse events attributable to the nivolumab component (for example, hepatitis or colitis) are managed per standard PD-1 toxicity guidelines with systemic corticosteroids.

---

The regulatory saga: Two CRLs and the 10-3 CTGTAC advisory committee vote

Tudriqev's path to FDA approval was one of the most contentious regulatory journeys in recent biopharma oncology history, navigating two Complete Response Letters (CRLs) before securing accelerated approval.

                     Tudriqev Regulatory Approval Timeline
                                       │
Nov 2024 (1st BLA) ─► Jul 22, 2025 (CRL #1) ─► Oct 20, 2025 (2nd Resub) ─► Apr 10, 2026 (CRL #2)
• Breakthrough Therapy   • Clinical/effectiveness  • Resubmitted BLA 125827     • Same clinical
  designation; BLA        deficiencies cited        • Single-arm IGNYTE           effectiveness concerns
  125827 filed            • Effect cannot be           design still contested      • FDA briefing docs
                           isolated from nivolumab                                called data unreliable
                                  │
                                  ▼
Jun 26, 2026 (3rd Resub) ──────► Jul 30, 2026 (AdCom) ──────► Aug 6, 2026 (Approval)
• Class 1 resubmission      • CTGTAC Votes 10-3      • FDA grants Accelerated
• Added 3-year IGNYTE         in favor of benefit-     Approval with Opdivo
  survival update              risk profile            (~4 days post-PDUFA)
• PDUFA target Aug 2, 2026  • Panel cited unmet need

1. First Complete Response Letter (July 22, 2025): Replimune submitted the original Biologics License Application (BLA 125827) in November 2024 under the accelerated approval pathway with Breakthrough Therapy designation. The FDA's first Complete Response Letter (CRL), dated July 22, 2025, identified clinical and statistical deficiencies—not chemistry, manufacturing, and controls (CMC) problems. Specifically, the agency concluded that the single-arm IGNYTE design was not adequate and well-controlled and could not isolate RP1's contribution from concurrent nivolumab.
2. Second Complete Response Letter (April 10, 2026): Replimune resubmitted the BLA (accepted October 20, 2025), but the FDA issued a second CRL on April 10, 2026 reiterating the same clinical-effectiveness concerns. Notably, the deficiency was clinical and statistical, not CMC-driven.
3. Third Resubmission (Accepted June 26, 2026): Replimune resubmitted BLA 125827 a third time with an updated 3-year overall survival analysis from the IGNYTE anti-PD-1-failed melanoma cohort. The FDA accepted the resubmission for Class 1 review with a target PDUFA action date of August 2, 2026.
4. Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting (July 30, 2026): The FDA convened its CTGTAC panel to deliberate whether the IGNYTE data constituted substantial evidence of effectiveness. FDA briefing documents released July 28, 2026 had called the response data "not interpretable" and "unreliable" and argued RP1's contribution could not be disentangled from nivolumab; Replimune shares fell more than 30% that day. Going against the agency's own reviewers, the committee voted 10 to 3 that the benefit-risk profile supported accelerated approval, citing the severe unmet need in post-anti-PD-1 melanoma.
5. Approval Action (August 6, 2026): Four days following the PDUFA target date, the FDA granted accelerated approval—the second oncolytic virus ever cleared in the United States.

---

How is Tudriqev dosed and administered?

Administering Tudriqev requires coordination between the medical oncology team, specialty surgical/interventional oncology injectors, and the specialty pharmacy.

                      Tudriqev + Nivolumab Dosing Schedule
                                       │
       ┌───────────────────────────────┴───────────────────────────────┐
       │                                                               │
[Dose 1 (Day 1)]                                                [Doses 2–8 (Every 2 Weeks)]
• Low-dose priming: 1 x 10^6 PFU/mL                             • High-dose therapy: 1 x 10^7 PFU/mL
• Total volume up to 10.0 mL                                    • Total volume up to 10.0 mL
• Tudriqev monotherapy only                                     • Tudriqev + IV Nivolumab (240 mg Q2W)
• Seroconversion / safety window                                • Continued for up to 8 total doses

Intratumoral Injection Schedule & Dosing Tiers

Tudriqev is supplied in single-dose frozen vials and administered via direct intratumoral injection into superficial cutaneous, subcutaneous, or nodal lesions using fine-gauge needles (typically 25G to 30G for superficial lesions, or ultrasound/CT guidance for deeper palpable nodes):

• Dose 1 (Week 1, Day 1): Low-concentration priming dose of $1.0 \times 10^6\text{ PFU/mL}$ ($1\text{ million PFU/mL}$). Total injection volume across all treated lesions is up to a maximum of 10.0 mL. This initial low dose allows seroconversion and blunts systemic febrile reactions. Nivolumab is not administered on Day 1.
• Doses 2 through 8 (Weeks 3, 5, 7, 9, 11, 13, and 15): Administered every 2 weeks at the higher concentration of $1.0 \times 10^7\text{ PFU/mL}$ ($10\text{ million PFU/mL}$), up to a maximum volume of 10.0 mL per session.
• Nivolumab Combination: Starting at Week 3 (coinciding with Tudriqev Dose 2), nivolumab 240 mg IV is administered every 2 weeks (or 480 mg IV every 4 weeks) following the completion of the intratumoral viral injections.
• Maintenance Phase: After completing up to 8 Tudriqev injection sessions (approximately 15 weeks), responding or stable patients continue on maintenance nivolumab 480 mg IV every 4 weeks for up to 24 months or until disease progression or unacceptable toxicity.

Injection Volume Allocation by Lesion Size

The treating clinician distributes the maximum 10.0 mL volume across accessible lesions based on lesion diameter:

Biosafety & Operational Handling

Because Tudriqev is a live, replication-competent modified HSV-1 virus, institutional protocols must incorporate Biosafety Level 1/2 precautions:

• Vials must be stored in an ultra-low temperature freezer at $-80^\circ\text{C}$ to $-60^\circ\text{C}$.
• Thawing occurs at room temperature (takes approximately 30–45 minutes) and must be injected within 4 hours of thawing.
• Healthcare personnel administering the injection must wear personal protective equipment (gloves, gown, face shield).
• Injection sites must be covered with occlusive dressings for at least 24 hours to prevent viral shedding or accidental transmission to household contacts (particularly pregnant women or immunocompromised individuals).

---

What does Tudriqev cost and how is it billed and reimbursed?

Reimbursement for Tudriqev sits entirely within the medical benefit under buy-and-bill or specialty pharmacy white-bagging frameworks, rather than retail pharmacy benefit channels.

Pricing Architecture & Course Cost

Replimune announced a list price (wholesale acquisition cost) of approximately $450,000 per treatment course, based on the median dose level for patients treated in the pivotal IGNYTE study. Because Tudriqev is dosed according to a patient's tumor burden—the full 10 mL maximum is distributed across injectable lesions every two weeks for eight consecutive doses—Chief Financial Officer Emily Hill confirmed that actual course cost will vary upward or downward with cumulative tumor volume and the number of treatment rounds required. Replimune expects to begin commercial shipment within approximately 60 days of approval and is launching with a patient access and reimbursement support program (ReplimuneConnect Plus).

In addition to Tudriqev vial acquisition, payer total cost of care must incorporate concurrent Opdivo loss of exclusivity in the BMS portfolio and standard IV infusion fees for the nivolumab component.

Billing Codes & Claims Processing

Following approval on August 6, 2026, Tudriqev will enter the market prior to the establishment of a permanent, product-specific CMS Level II Healthcare Common Procedure Coding System (HCPCS) J-code. P&T committees and billing revenue-cycle teams must prepare for a 6-to-9 month transition:

Payer Utilization Management & Prior Authorization Criteria

Because Tudriqev is an accelerated approval biologic with a $450,000 list price, commercial payers (e.g., UnitedHealthcare, Elevance, Cigna, Aetna) and Medicare Advantage plans are implementing strict prior authorization (PA) criteria:

1. Confirmed Diagnosis: Histologically confirmed unresectable Stage III or Stage IV cutaneous melanoma.
2. Prior Anti-PD-1 Progression: Documented progression on or within 12 weeks of completing $\ge 8\text{ consecutive weeks}$ of anti-PD-1 therapy (pembrolizumab or nivolumab $\pm$ ipilimumab or relatlimab).
3. BRAF Status Consideration: For patients harboring $BRAF\text{ V600}$ mutations, documentation of prior or planned exposure to BRAF/MEK inhibitor targeted therapy (e.g., dabrafenib/trametinib, encorafenib/binimetinib), or clinical justification for prioritizing immunotherapy.
4. Injectable Lesion Verification: Attestation from the treating oncologist/surgeon that the patient has at least one injectable cutaneous, subcutaneous, or nodal lesion accessible without major surgical cutdown.
5. Initial Authorization Period: 16 weeks (covering the 8 bi-weekly injection cycles), with continuation of single-agent nivolumab granted for 12-month intervals upon proof of disease control or absence of progression.

---

How does Tudriqev compare with Amtagvi in the post-anti-PD-1 melanoma setting?

The approval of Tudriqev establishes a major clinical and commercial fork in the road for refractory melanoma management, pitting an off-the-shelf oncolytic virus against Iovance Biotherapeutics' Amtagvi (lifileucel), the autologous tumor-infiltrating lymphocyte (TIL) therapy approved in February 2024.

                  Post-Anti-PD-1 Melanoma Modality Selection
                                       │
         ┌─────────────────────────────┴─────────────────────────────┐
         │                                                           │
   [Tudriqev (RP1)]                                            [Amtagvi (Lifileucel)]
   • Off-the-shelf viral biologic                              • Autologous cell therapy (TIL)
   • List Price: ~$450,000                                     • List Price: ~$562,000–$563,000
   • Outpatient clinic administration                          • Inpatient ICU admission required
   • No lymphodepletion, no IL-2                               • High-dose Cy/Flu lymphodepletion
   • Efficacy: ORR 24.2%, mDOR 14.1 mo                         • High-dose IL-2 (aldesleukin) support
   • Ideal: Frail, elderly, outpatient                         • Efficacy: ORR 31.5%, mDOR NR
     or rapid disease progression                              • Ideal: Fit, younger, specialized center

---

What is the confirmatory IGNYTE-3 trial and what is the accelerated-approval withdrawal risk?

Because Tudriqev received accelerated approval under Section 506(c) of the Federal Food, Drug, and Cosmetic Act, Replimune is legally obligated to verify and describe clinical benefit in an adequate, well-controlled confirmatory trial.

IGNYTE-3 Trial Design (NCT06264180)

The post-marketing confirmatory study is IGNYTE-3, an international, randomized, open-label Phase 3 trial:

• Study Population: Approximately 400 patients (ages 12 and older) with unresectable Stage IIIB–IV cutaneous melanoma whose disease progressed on both an anti-PD-1 antibody and an anti-CTLA-4 antibody (given as a combination or in sequence), or who are not candidates for anti-CTLA-4 therapy.
• Randomization (1:1):
  • Arm A (Investigational): Tudriqev intratumoral injections every two weeks for up to eight doses + IV nivolumab.
  • Arm B (Control / Treatment of Physician's Choice): Physician-selected standard therapy—combination nivolumab + relatlimab (Opdualag), anti-PD-1 monotherapy (nivolumab or pembrolizumab), or single-agent chemotherapy (dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel).
• Primary Endpoint: Overall survival (OS), with progression-free survival as a key secondary endpoint.
• Target Readout Timeline: Primary completion is anticipated in 2029, with mature OS readout expected around 2030.

                      IGNYTE-3 Phase 3 Trial Architecture
                                       │
            ┌──────────────────────────┴──────────────────────────┐
            │                                                     │
   [Arm A: Experimental (1/2)]                  [Arm B: Treatment of Physician's Choice (1/2)]
   • Tudriqev IT + Nivolumab IV                 • Nivolumab + Relatlimab (Opdualag)
   • 8 injection sessions + nivolumab Q2W/Q4W   • Anti-PD-1 monotherapy (nivo or pembro)
   • Continued until progression / toxicity     • Single-agent chemo (dacarbazine, temozolomide,
                                                  or paclitaxel / nab-paclitaxel)

Regulatory Withdrawal Risk Analysis

Under the Food and Drug Omnibus Reform Act (FDORA) enacted by Congress in late 2022, the FDA possesses streamlined authority to withdraw accelerated approvals if a sponsor fails to conduct post-approval studies with due diligence or if the confirmatory trial fails to demonstrate statistically significant clinical benefit.

In the PD-1 checkpoint-immunotherapy approvals in 2026 landscape, multiple accelerated approval indications (e.g., atezolizumab in urothelial carcinoma, pembrolizumab in gastric cancer subgroups) have been voluntarily withdrawn or formally revoked following negative confirmatory Phase 3 readouts.

For Tudriqev, IGNYTE-3 is a genuinely rigorous—and therefore genuinely risky—test. Unlike a chemotherapy-only control, Arm B permits active immunotherapy options including Opdualag (nivolumab + relatlimab) and anti-PD-1 monotherapy, meaning Tudriqev plus nivolumab must demonstrate an overall-survival advantage over contemporary standard-of-care checkpoint regimens, not merely over salvage chemotherapy. Three considerations frame the risk:

1. Active Immunotherapy Control: A control arm dominated by effective checkpoint inhibitors sets a high efficacy bar; failure to beat OS would put the accelerated approval in jeopardy.
2. 1:1 Randomization: The balanced design yields a cleaner comparison than the original single-arm IGNYTE but depends on full enrollment (~400 patients) across a heavily pretreated population.
3. Survival Endpoint: Because the primary endpoint is OS rather than response rate, mature readout is not expected until around 2030—leaving a multi-year window during which the indication could be withdrawn if the trial falters.

---

Frequently Asked Questions

Is Tudriqev the same drug as RP1, and is it a gene therapy or an oncolytic virus?

Yes. Tudriqev is the proprietary commercial brand name for vusolimogene oderparepvec-wtpg, which was developed in pre-commercial clinical trials under the code name RP1. Technically, Tudriqev is classified by the FDA as an oncolytic viral therapy under the jurisdiction of the Center for Biologics Evaluation and Research (CBER) and the Office of Therapeutic Products (OTP). While it contains genetic modifications (HSV-1 encoding GALV-GP-R(-) and GM-CSF), its primary therapeutic action is selective viral replication, oncolysis, and immune priming, rather than replacing a defective human gene.

Why was Tudriqev rejected twice before its August 2026 approval?

The FDA issued two Complete Response Letters (dated July 22, 2025 and April 10, 2026) over clinical and statistical deficiencies—not chemistry, manufacturing, and controls (CMC) problems. The agency concluded that the single-arm IGNYTE study was not an adequate and well-controlled investigation and could not isolate RP1's contribution to the observed responses from concurrent nivolumab. Replimune ultimately overcame these concerns by submitting a third resubmission (accepted June 26, 2026) that added a 3-year overall survival update from IGNYTE and emphasized the severity of the unmet need, culminating in a 10-3 favorable advisory committee vote on July 30, 2026.

Does Tudriqev have a permanent HCPCS J-code yet, or is it billed under unclassified codes?

As of August 2026, Tudriqev does not have a permanent, product-specific Level II HCPCS J-code. During the initial 6-to-9 month commercial launch phase, outpatient hospital departments and physician practices must bill Tudriqev under unclassified biological codes: J3590 (Unclassified biologics) for physician offices, or C9399 (Unclassified drugs or biologicals) for hospital outpatient clinics, accompanied by the National Drug Code (NDC), exact dose, and invoice details. A permanent J-code is expected from CMS in 2027.

Will commercial payers and Medicare cover Tudriqev given its accelerated approval status?

Yes, but coverage will be tightly managed under medical-benefit prior authorization. Medicare Part B covers FDA-approved antineoplastic agents for their labeled indications under standard local coverage determinations (LCDs). Commercial payers (e.g., UnitedHealthcare, Aetna, Cigna) are establishing PA criteria requiring documentation of verified Stage III/IV cutaneous melanoma, confirmed progression after at least 8 weeks of anti-PD-1 therapy, and the presence of accessible injectable lesions.

---

Sources

1. U.S. Food and Drug Administration (FDA): FDA Grants Accelerated Approval to Vusolimogene Oderparepvec-wtpg in Combination with Nivolumab for Advanced Cutaneous Melanoma. FDA Approved Drugs Notification, August 6, 2026. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma.
2. Replimune Group Inc.: Replimune Announces FDA Accelerated Approval of TUDRIQEV™ in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma. Investor Relations Press Release, August 6, 2026. Available at: https://ir.replimune.com/news-releases/news-release-details/replimune-announces-fda-accelerated-approval-tudriqevtm.
3. Journal of Clinical Oncology (JCO): Wong MK, Sacco JJ, Robert C, et al. Primary Efficacy and Biomarker Analysis of RP1 Combined with Nivolumab in Patients with Advanced Cutaneous Melanoma Failing Prior Anti-PD-1 Therapy (IGNYTE). J Clin Oncol. 2025;43(33):3589-3599. DOI: 10.1200/JCO-25-01346.
4. ClinicalTrials.gov: Study of RP1 in Patients with Advanced and/or Refractory Solid Tumors (IGNYTE). Identifier: NCT03767348.
5. ClinicalTrials.gov: A Study of RP1 (Vusolimogene Oderparepvec) Plus Nivolumab vs Physician's Choice in Advanced Melanoma That Has Progressed on Anti-PD-1 and Anti-CTLA-4 Therapy (IGNYTE-3). Identifier: NCT06264180.
6. U.S. FDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC): Briefing Document for BLA 125827: Vusolimogene Oderparepvec-wtpg. Meeting Date: July 30, 2026.
7. Centers for Medicare & Medicaid Services (CMS): Healthcare Common Procedure Coding System (HCPCS) Level II Coding Guidelines for Unclassified Biologicals (J3590 / C9399).